We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest close session, Novavax (NVAX - Free Report) was up +1.53% at $10.79. This move outpaced the S&P 500's daily loss of 0.77%. Meanwhile, the Dow lost 0.67%, and the Nasdaq, a tech-heavy index, lost 0.92%.
Shares of the vaccine maker witnessed a gain of 14.8% over the previous month, beating the performance of the Medical sector with its loss of 3.65%, and the S&P 500's gain of 0.96%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.37 per share. This would mark year-over-year growth of 40.32%. Our most recent consensus estimate is calling for quarterly revenue of $42.96 million, down 39.01% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.46 per share and revenue of $357.88 million. These results would represent year-over-year changes of -117.83% and -68.15%, respectively.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.05% higher. Novavax is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 176, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
In the latest close session, Novavax (NVAX - Free Report) was up +1.53% at $10.79. This move outpaced the S&P 500's daily loss of 0.77%. Meanwhile, the Dow lost 0.67%, and the Nasdaq, a tech-heavy index, lost 0.92%.
Shares of the vaccine maker witnessed a gain of 14.8% over the previous month, beating the performance of the Medical sector with its loss of 3.65%, and the S&P 500's gain of 0.96%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.37 per share. This would mark year-over-year growth of 40.32%. Our most recent consensus estimate is calling for quarterly revenue of $42.96 million, down 39.01% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.46 per share and revenue of $357.88 million. These results would represent year-over-year changes of -117.83% and -68.15%, respectively.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.05% higher. Novavax is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 176, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.